news aktuell GmbH

COUNTRY QUEEN IS THE FIRST KENYAN LICENSED BRANDED SERIES ON NETFLIX

Share

Country Queen, which premiered in 190 countries exclusively on Netflix 15th of July, is the first high-quality drama series from East Africa to reach a global audience! Launching as No. 1 TV Show in Kenya on Netflix for two weeks in a row, the series continues to gain stellar reviews, more traction and global recognition.

COUNTRY QUEEN Poster portrait
COUNTRY QUEEN Poster portrait

When death awakens a sleepy village, its past threatens to haunt the present.

Berlin - COUNTRY QUEEN is a family drama series set in contemporary Kenya. The new, original drama series, first out of Kenya, is adding to the growing list of dynamic African content. The past and present collide in this David vs. Goliath story when a mining company threatens to destroy the rural home of AKISA MUTUNGA, an ambitious event planner, who is pitted against a deadly businesswoman, whose husband she is entangled with. Akisa finds herself in the midst of a love triangle, as she struggles to find her place in life by finding her true love and lost son.

Issues of land grabbing and exploitation form the tapestry against which the fractured personal lives and relationships of Country Queen's main characters play out. The fight for land becomes a fight for redemption and truth. The characters have to face the consequences of their own choices. The fictional story carries many elements of truth that speak to a range of issues such as family disputes, land ownership and exploitation that affect millions of people in Africa and worldwide.

Good Karma Fiction, together with ten up and coming Kenyan writers, developed the narrative. Good Karma Fiction's managing directors are the show runners of COUNTRY QUEEN. Season 1 was co-financed by German-French channel Arte/ZDF, German Government/DW Akademie, a private investor and Netflix.

https://www.countryqueen.tv/

#CountryQueenKenya

Contacts

Good Karma Fiction
Contact:
Waltraud Ehrhardt
ehrhardt@goodkarmafiction.com

Images

COUNTRY QUEEN Poster portrait
COUNTRY QUEEN Poster portrait
Download
Vivienne & Max.
Vivienne & Max.
Download

About news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

As wholly owned subsidiary of dpa, news aktuell provides business and organizations with effective access to media and consumers. Via the smart tools ots and zimpel, PR content accesses all media formats, including classical print, high click-rate online portals and social networks. In addition, news aktuell publishes all its customers’ PR content on www.presseportal.de, one of the PR portals with the greatest reach in Germany. By this means, all the relevant multipliers are reached globally, from editors, via digital influencers right up to specialist bloggers and interested consumers. news aktuell has been on the market since 1989. The company, with a staff complement of more than 135, has its headquarters in Hamburg. Other offices are in Berlin, Dusseldorf, Frankfurt und Munich.

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Grünenthal starts Phase III trials for resiniferatoxin in osteoarthritis-related pain ​18.8.2022 13:11:21 CEST | Press release

Global Phase III programme to enable marketing authorisation in the EU, the US and Japan for an innovativenon-opioid investigational medicine. The programme will be conducted across approx. 200 study sites and include more than 1800 patients suffering from pain associated with osteoarthritis. Globally, more than 300 million patients suffer from osteoarthritis[1]. The global osteoarthritis market is expected to grow to approximately $11.0 billion in 2025[2]. Aachen, Germany – 18 August 2022 –Grünenthal announced today that the company has enrolled the first patient in its global clinical Phase III programme for resiniferatoxin (RTX). RTX is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist, with a well-validated mechanism of action. The discovery of TRPV1 was awarded the Nobel Prize of Physiology or Medicine in 2021. If approved, resiniferatoxin may provide patients with long-lasting pain relief with a favourable safety profile. Grünenthal’s Phase III programme wi

An ordeal that ends on a plate in a tourist resort: Live transports of calves to the Canary Islands9.8.2022 16:47:11 CEST | Press release

Every week, cattle are shipped to the Canary Islands under unacceptable conditions. These transports are extremely long. The animals stand on the truck for even more than 100 hours non-stop. Now, in summer, sweltering heat must be added as well as poor water supply, no or too little food, bedding of excrements and urine, lack of space, and an acrid ammonia smell. Once on the islands, the animals, only a few months old, await death in the slaughterhouse. A trade that is enhanced by subsidies and slaughter premiums .

Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million4.8.2022 09:00:00 CEST | Press release

Aachen, Germany – 4 August 2022 – Grünenthal and Shionogi announced today that they have entered into a licensing agreement for Grünenthal’s investigational medicine Resiniferatoxin (“RTX”). Shionogi obtained the exclusive rights to commercialise Grünenthal’s asset in Japan for pain associated with osteoarthritis of the knee. RTX is currently in Phase III of clinical development for the treatment of patients with moderate to severe pain associated with knee osteoarthritis. Osteoarthritis, a progressive and often painful joint disease, is an indication with high unmet medical need. If approved, RTX could become a well-tolerated, non-opioid therapy option for patients, providing long-lasting pain relief and functional improvement of the affected knee joints. Under the terms of the agreement, Shionogi will obtain the exclusive commercialisation rights for RTX in Japan for a total consideration of up to $ 525 million plus additional sales based payments. Thereof, Shionogi will pay $ 75 mil

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom